Pharmacological Treatment Options for Coronavirus Disease-19 in Renal Patients

Jonny1, Laurencia Violetta1, Arief Sjamsulaksan Kartasasmita2

  • 1Nephrology Division, Department of Internal Medicine, Gatot Soebroto Indonesia Army Central Hospital, Jakarta, Indonesia.

Insights

Patients with chronic kidney disease (CKD) need specific COVID-19 drug guidance. This review details necessary dosage adjustments and renal side effects for managing SARS-CoV-2 in kidney patients.

Area of Science:

  • Nephrology
  • Infectious Diseases
  • Pharmacology

Background:

  • Patients with chronic kidney disease (CKD) face increased risk from SARS-CoV-2 infection.
  • Existing comorbidities in CKD patients exacerbate COVID-19 severity.
  • No specific guidelines exist for managing COVID-19 in renal impairment.

Purpose of the Study:

  • To review dosing adjustments for COVID-19 drugs in patients with kidney dysfunction.
  • To identify potential renal side effects of common COVID-19 treatments.
  • To inform nephrologists on optimizing SARS-CoV-2 management in CKD.

Main Methods:

  • Non-systematic review of COVID-19 treatments.
  • Exploration of clinical trial databases and search engines.
  • Analysis of drug information for renal dosing and side effects.

Main Results:

  • Several antivirals and monoclonal antibodies require dosage modification for kidney dysfunction.
  • Monitoring for renal side effects is crucial with combined drug therapies.
  • Optimal therapeutic effects depend on careful dose titration based on renal function.

Conclusions:

  • Nephrologists must carefully adjust COVID-19 drug dosages based on renal function.
  • Close monitoring for renal side effects is essential to prevent further kidney damage.
  • Further research is needed to establish safety and efficacy in renal patients.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
561
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
188
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
46
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
17
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
104
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
68